Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder

The purpose of this study is to evaluate how effective quetiapine versus placebo is when added to an existing therapy, in reducing the symptoms of PTSD.

Official Title

A Multicentre, Parallel Group, Randomised, Double Blind, Placebo Controlled Study of the Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder

Conditions

Post-Traumatic Stress Disorder

Study Type

Interventional

Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study

Further Details

Primary Outcome Measures:

• Clinical Administered PTSD Scale (CAPS2)

Secondary Outcome Measures:

• Hamilton Depression Scale (HAM-D)
• Hamilton Anxiety Scale (HAM-A)
• Posttraumatic Stress Disorder Checklist (PCL)
• Clinical Global Impressions (CGI)

Study Start

December 2004

Eligibility & Criteria

• Ages Eligible for Study: 18 Years – 65 Years
• Genders Eligible for Study: Both

Inclusion Criteria:

• Hospitalised and non-hospitalised patients / Veteran or Civilian / Have had symptoms of PTSD for a minimum of 12 months prior to giving consent to the study

Exclusion Criteria:

• History of psychotic condition / quetiapine or other anti-psychotics not worked previously / Taking prohibited medications (mood stabilizers / substance abuse)

Total Enrolment

90

Contact Details

• Brisbane, Queensland, Australia; Recruiting
• Adelaide, South Australia, Australia; Recruiting
• Melbourne, Victoria, Australia; Recruiting

Contact AstraZeneca for more information